Novolight DX
Hematological Analysis Devices
Health Tech & Life Sciences
Non Active, Aug 2025 ceased to operate
Company Overview
Snapshot
Founded in June 2023 by Ben Leshem and Ittai Madar, Novolight DX operates with 1–10 employees. In January 2024, Novolight DX received a grant from the Israel Innovation Authority.
Business overview
Novolight DX develops hematological analysis devices, focusing on the health tech and life sciences sector. The company's core technology is applied to diagnostics, serving healthcare providers and laboratories within the broader healthcare industry.
Log in to access full profile ›Company Intelligence Q&A
- What is Novolight DX's current operational status?
- Novolight DX is currently non-active and ceased operations in August 2025.
- When was Novolight DX founded and by whom?
- Novolight DX was founded in June 2023 by Ben Leshem and Ittai Madar.
- What is Novolight DX's primary business focus?
- Novolight DX specializes in hematological analysis devices within the Health Tech & Life Sciences sector, with a focus on diagnostics.
- Which markets does Novolight DX serve?
- Novolight DX targets the healthcare market, specifically serving providers and laboratories.
- What was a significant funding event for Novolight DX?
- In January 2024, Novolight DX received a grant from the Israel Innovation Authority.